Tumor Killing Assay
Tumor Killing Assay - Related Videos
05:09
Repetitive Tumor Challenge Assay: An In Vitro Culture Assay to Evaluate Chimeric Antigen Receptor (CAR) T Cells for Repetitive Tumor Killing Potential
0 Views •
2025
In this video, we demonstrate the repetitive tumor challenge assay to evaluate the CAR T cells’ repetitive tumor killing potential during high tumor cell loads. Further, the CAR T cells can be analyzed using flow cytometry to determine the different subpopulations of CAR T cells in the sample.
09:49
Antigen Specific In Vivo Killing Assay using CFSE Labeled Target Cells
0 Views •
Cited by 39 •
2010
Many infections elicit a strong CTL response, but occasionally, the quantity of responding cells does not correlate to control of the pathogen1. One measure of CTL quality is their ability to kill specifically2. CFSE labeling of target cells can be used to investigate this CTL response quality in vivo3,4.
08:19
A Spheroid Killing Assay by CAR T Cells
0 Views •
Cited by 21 •
2018
This protocol is designed to assess immunotherapeutic redirected T-cell (CAR T-cell) cytotoxicity against 3D structured cancerous cells (spheroids) in real time.
03:17
Soft Agar Overlay Assay for Detecting Bacteriocin-Mediated Killing in Pseudomonas syringae
0 Views •
2025
Source: Hockett, K. L., and Baltrus, D. A. Use of the Soft-agar Overlay Technique to Screen for Bacterially Produced Inhibitory Compounds. J. Vis. Exp. (2017)This video demonstrates the procedure for detecting bacteriocin-mediated killing by spotting supernatant from an antibiotic-induced donor strain onto a soft agar overlay containing a test strain. Clear zones formed after incubation indicate bacterial inhibition.
07:53
An In vitro FluoroBlok Tumor Invasion Assay
0 Views •
Cited by 23 •
2009
This video demonstrates how to measure cell invasion through cell culture inserts using a fluorescence-based methodology.
FAQs
Researchers expose tumor targets to candidate effector cells, therapeutic agents, or engineered cells under defined co-culture conditions. Comparing the resulting tumor-cell death or reduced viability shows how strongly each candidate affects the targets. This design supports potency comparisons across different types of cancer treatments while keeping the tumor-cell response as the measured outcome.
Defined conditions make results easier to compare because the tumor targets and candidate treatments are assessed within a specified experimental setting. Changes in tumor-cell number, metabolic activity, or another measurable readout can then be related to the tested effector cells or treatment. Consistent conditions also help researchers examine possible mechanisms of cancer-cell elimination.
Tumor-cell number, metabolic activity, and other measurable indicators can reveal whether treatment exposure has reduced tumor-cell viability or increased cell death. Using these readouts allows researchers to quantify an experimental response rather than relying only on observation. The selected measurement can therefore support comparisons of treatment potency and evaluation of how effectively candidates eliminate tumor cells.
This assay evaluates tumor-cell responses in vitro before a candidate advances to more complex models. Its controlled format helps researchers compare potency, assess cancer-cell elimination, and identify promising treatments at an earlier stage. However, the results serve as an experimental basis for further evaluation rather than replacing studies in more complex systems.
A typical workflow brings tumor targets together with candidate effector cells, therapeutic agents, or engineered cells under defined co-culture conditions. After the exposure period, researchers quantify tumor-cell death or reduced viability using cell number, metabolic activity, or another measurable readout. The resulting measurements support comparisons among candidates or treatment conditions.
Researchers use tumor killing assays to compare treatment potency, investigate how cancer cells are eliminated, and evaluate responses to candidate interventions. The approach supports immunotherapy development and drug screening, including studies of immune cells, therapeutic agents, and engineered cells. It can also help prioritize candidates before they are examined in more complex models.
By measuring tumor-cell death or reduced viability under defined conditions, researchers can compare responses to different treatment conditions and examine combination strategies. The assay provides a way to evaluate whether a combined approach produces a measurable change in tumor-cell elimination relative to candidate treatments assessed separately. These results can guide further optimization before more complex testing.